
RCL · NYSE
The supplied consensus is Buy, with all 18 analysts in that category and a mean price target of $360. Low and high targets are not provided, so the target cluster, full spread, and most- and least-bullish analysts cannot be identified from the evidence. No specific target changes or rating revisions over the past week are reported. The evidence does show a substantive debate around the Sandals deal: Zacks cites strong bookings and cash flow as support for a new growth avenue, while also flagging leverage and execution risk. Separately, Zacks cautions that estimate revisions may not drive near-term share-price gains; the supplied material does not attribute these views to named analysts.